Non-Small Cell Lung Cancer (NSCLC)

>

Latest News

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.
Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC

September 30th 2025

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.
TTFields After SRS Prolongs Intracranial Response in Brain Metastatic NSCLC

September 30th 2025

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC
Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

September 26th 2025

Employing Comprehensive Genomic Testing in the NSCLC Paradigm
Employing Comprehensive Genomic Testing in the NSCLC Paradigm

September 24th 2025

Evaluating the Top EGFR+ NSCLC Treatment Combinations
Evaluating the Top EGFR+ NSCLC Treatment Combinations

September 20th 2025

Latest CME Events & Activities

More News

lung cancer

Osimertinib Extends Disease-Free Survival in Resected EGFR-Mutated NSCLC in Phase 3 ADAURA Trial

Hannah Slater
November 21st 2020

These study results suggest that osimertinib as adjuvant therapy is an effective treatment strategy for patients with stage IB to IIIA EGFR-positive non-small cell lung cancer following complete tumor resection.

FDA logo

FDA Approves Additional Dosing Option of Durvalumab for Stage III NSCLC, Advanced Bladder Cancer

Hannah Slater
November 20th 2020

The FDA approved a 1500 mg fixed dose of durvalumab (Imfinzi) administered every 4 weeks for the treatment of unresectable stage III non-small cell lung cancer after chemoradiation therapy and previously treated advanced bladder cancer.

<1
...
282930313233>